IPHA
IPHA clinical trials: Innate Pharma SA
Every trial on ClinicalTrials.gov where Innate Pharma SA is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 32
- Trials linked
- 21
- As lead sponsor
- 11
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
IPHA on the catalyst calendar · IPHA registry changes
- Primary completion Apr 2028Sponsor estimatePhase 1NCT06781983Safety and Tolerability of IPH4502 in Patients With Advanced Solid TumorsInnate Pharma · Advanced or Metastatic Solid TumorsActive, not recruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 2NCT05742607IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)Innate Pharma · Non Small Cell Lung CancerRecruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 8, 2026ActualPhase 2NCT03902184IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell LymphomaInnate Pharma · Lymphoma, T-CellCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2012ActualPhase 2NCT01222286Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple MyelomaInnate Pharma · Smoldering Multiple MyelomaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07539194Evaluation of the Performance and Safety of a Single-dose Hyaluronic Acid (Promovia Hydro Balance) in the Treatment of Non-traumatic...Innate srl · Meniscus TearsRecruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2026Sponsor estimateNo phase registeredNCT07367295Prospective Clinical Study, Using a Medical Device (RepHegyn) as an Adjuvant in the Treatment of Fungal (Candidiasis) and Bacterial...Innate srl · Bacterial InfectionsNot yet recruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2024ActualNo phase registeredNCT07331181Evaluation of Performance and Safety of INNEA and INNEA AQUA for the Treatment of Cheek and décolletage WrinklesInnate srl · WrinkleRecruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 6, 2026ActualPhase 1/Phase 2NCT06088654Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin LymphomaInnate Pharma · Non Hodgkin LymphomaTerminatedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 30, 2026Sponsor estimateNo phase registeredNCT07367061Clinical Investigation to Assess Safety and Efficacy of INNEA AQUA in Adult Women With Vulvo-Vaginal Atrophy (VVA)Innate srl · Vulvo Vaginal AtrophyActive, not recruitingIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 19, 2023ActualPhase 1NCT05321147Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2Innate Pharma · Peripheral T Cell LymphomaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 28, 2023ActualPhase 1/Phase 2NCT02643550Study of Monalizumab and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckInnate Pharma · Head and Neck NeoplasmsCompletedIPHALeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 24, 2021ActualPhase 1NCT03665129IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid TumorsInnate Pharma · Advanced Solid TumorsTerminatedIPHALeadAZNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2020ActualPhase 1NCT02593045Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)Innate Pharma · Cutaneous T-Cell LymphomaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 29, 2018ActualPhase 1/Phase 2NCT02557516Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLLInnate Pharma · Chronic Lymphocytic LeukemiaTerminatedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 17, 2016ActualPhase 2NCT01687387Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)Innate Pharma · Acute Myeloid LeukemiaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1/Phase 2NCT02331875Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral CavityInnate Pharma · Squamous Cell Carcinoma of the Oral CavityTerminatedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2011ActualPhase 1NCT00552396An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple MyelomaInnate Pharma · Multiple MyelomaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2012ActualPhase 2NCT00999830Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple MyelomaInnate Pharma · Multiple MyelomaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2014ActualPhase 1NCT01370902Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid ArthritisInnate Pharma · InflammationCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2013ActualPhase 1NCT01256073A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute...Innate Pharma · Acute Myeloid LeukemiaCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2013ActualPhase 1NCT01217203Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma...Innate Pharma · Patients With Multiple Myeloma Experiencing aCompletedIPHALead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 11, 2022ActualPhase 3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and...AstraZeneca · Squamous Cell Carcinoma of the Head and NeckActive, not recruitingAZNLeadIPHACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 2027Sponsor estimatePhase 1NCT05143970A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With...Institut Paoli-Calmettes · Metastatic CancerActive, not recruitingIPHACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2028Sponsor estimatePhase 2NCT04984837Study of Lacutamab in Peripheral T-cell LymphomaThe Lymphoma Academic Research Organisation · Peripheral T Cell LymphomaActive, not recruitingIPHACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 5, 2024ActualNo phase registeredNCT03015038Study of the Immune Response in Colon AdenocarcinomaInstitut National de la Santé Et de la Recherche Médicale, France · Colon AdenocarcinomaCompletedIPHACollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 7 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner